Alvotech streymir kynningu fyrir fjárfesta 3. apríl 2024 kl. 12:15 að íslenskum tíma
April 03, 2024 06:43 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið myndi streyma stuttri kynningu fyrir fjárfesta kl. 12:15 að íslenskum tíma í dag, 3. apríl 2024. Anil Okay, framkvæmdastjóri viðskipta mun þar...
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
April 03, 2024 06:43 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a...
Alvotech Announces Increase in Number of Own Shares
March 22, 2024 16:15 ET
|
Alvotech
REYKJAVIK, Iceland, March 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
Alvotech tilkynnir um útgáfu eigin hlutabréfa
March 22, 2024 16:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að stjórn fyrirtækisins hefði ákveðið að gefa út þrettán milljón (13.000.000) nýja almenna hluti í félaginu. Dótturfélag Alvotech, Alvotech Manco ehf....
Alvotech Announces Increase in Number of Own Shares
March 22, 2024 16:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share...
Alvotech birtir uppgjör fyrir árið 2023 og kynnir nýjustu áfanga í rekstri félagsins
March 20, 2024 16:15 ET
|
Alvotech
Heildartekjur á árinu 2023 voru 93,4 milljónir dollara, sem er 10% aukning frá fyrra áriSölutekjur á árinu 2023 voru 48,7 milljónir dollara, samanborið við 24,8 milljónir dollara á árinu 2022, og voru...
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
March 20, 2024 16:15 ET
|
Alvotech
Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up...
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
March 20, 2024 16:15 ET
|
Alvotech
Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up...
Alvotech heldur uppgjörsfund fyrir árið 2023 í beinu streymi þann 21. mars nk. kl. 12:00 að íslenskum tíma
March 05, 2024 16:01 ET
|
Alvotech
Fjárfestadagur, sem einnig verður sendur út á vefnum, verður haldinn föstudaginn 22. mars nk. Alvotech (NASDAQ: ALVO) birtir ársuppgjör fyrir 2023 að kvöldi miðvikudagsins 20. mars nk., eftir lokun...
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
March 05, 2024 16:01 ET
|
Alvotech
Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024 Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar...